neratinib + temsirolimus
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-mutant Non-Small Cell Lung Cancer
Conditions
HER2-mutant Non-Small Cell Lung Cancer
Trial Timeline
Jul 1, 2013 → Oct 6, 2017
NCT ID
NCT01827267About neratinib + temsirolimus
neratinib + temsirolimus is a phase 2 stage product being developed by Puma Biotechnology for HER2-mutant Non-Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01827267. Target conditions include HER2-mutant Non-Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01827267 | Phase 2 | Completed |
| NCT00838539 | Phase 1 | Completed |
Competing Products
1 competing product in HER2-mutant Non-Small Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Trastuzumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |